The Meshalkin Research Institute of Circulation Pathology and the Hertzen Moscow Oncology Research Institute have purchased Elekta Axesse systems.

Elekta Axesse will be delivered with Elekta VMAT (Volumetric Modulated Arc Therapy), which enables faster treatment time and more accurate targeting of the dose. Hertzen will be the first clinic in Russia to provide this technology to patients, according to Elekta.

The advanced technology is delivered with Mosaiq, the integrated suite of EMR software in oncology, the company said.